Everand Logo

Welcome to Everand!

  • NPR

    Johnson & Johnson Executive Says Vaccine Works Where It Counts: Preventing Deaths

    by Ailsa Chang Jan 29, 2021 3 minutes
    The Johnson & Johnson COVID-19 vaccine, pictured in December, is 66% effective at preventing moderate and severe disease. But Dr. Paul Stoffels of Johnson & Johnson says what matters more is preventing hospitalizations and deaths, which it did completely.

    Dr. Paul Stoffels, the chief scientific officer at Johnson & Johnson, told NPR on Friday that the topline results from the company's coronavirus vaccine study fail to tell the full story about just how effective it actually is.

    Johnson & Johnson said that 28 days after vaccination, its vaccine is 66% effective in preventing moderate to severe cases of COVID-19. But Stoffels says that Johnson & Johnson's vaccine is very effective where it matters most: preventing hospitalizations and deaths.

    "We showed that there was an 85% efficacy against severe disease and a complete protection against hospitalization and

    You’re reading a preview, subscribe to read more.

    More from NPR

    NPR3 min read
    Bearing Witness, Celebrating Strength: How Poetry Has Changed Lives For NPR's Audience
    From sparking the imagination to helping with mental health, listen to poems read by NPR readers and see how poetry has affected their lives.
    NPR3 min readAmerican Government
    Who Is Hope Hicks, The Former Trump Adviser Testifying In New York Criminal Trial?
    Hope Hicks was a communications director for the Trump White House and prosecutors may question her on her knowledge of the deals made during his first presidential run.
    NPR3 min read
    Scientists Welcome New Rules On Marijuana, But Research Will Still Face Obstacles
    When marijuana becomes a Schedule III instead of a Schedule I substance under federal rules, researchers will face fewer barriers to studying it. But there will still be some roadblocks for science.

    Related Books & Audiobooks